West Pharmaceutical signals 10%-11% 2026 organic revenue growth and $8.85-$9.05 adjusted EPS amid leadership transition
Seeking Alpha ·
Earnings Call Insights: West Pharmaceutical Services (WST) Q2 2026 "I am pleased to report strong second quarter results which exceeded our expectations on the top and bottom line." (Non-Independent Chair of the Board, President & CEO Eric Green) "Revenues of $872 million were up
DYAX Investor Sentiment
Bullish (Long) 45% · Bearish (Short) 55%
362 participants
Related News
- First Mid Bancshares raises dividend by 4% to $0.26
- Horizon projects 4.30%-4.35% net interest margin in H2 2026 while keeping mid-single-digit loan and deposit growth outlook
- Howden Joinery Group Plc 1H GAAP EPS of £0.16, revenue of £1.03B
- T-Mobile signals $18.4B-$18.8B 2026 adjusted free cash flow as it maintains ~$77B service revenue outlook
- Mortgage rates up for third straight week
- Roche jumps despite reiterated 2026 outlook
